IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


(Investigative Ophthalmology and Visual Science. 2005;46:3323-3330.)
© 2005 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.04-1210

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silva, R. L. e
Right arrow Articles by Campochiaro, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silva, R. L. e
Right arrow Articles by Campochiaro, P. A.

Suppression and Regression of Choroidal Neovascularization by Polyamine Analogues

Raquel Lima e Silva,1,2,3 Yoshitsugu Saishin,1,2,3 Yumiko Saishin,1,2 Hideo Akiyama,1,2 Shu Kachi,1,2 Sadia Aslam,1,2 Brian Rogers,1,2 Tye Deering,1,2 Yuan Yuan Gong,1,2 Sean F. Hackett,1,2 Hong Lai,1 Benjamin J. Frydman,4,5 Aldonia Valasinas,4 Laurence J. Marton,6 and Peter A. Campochiaro1,2

1From the Departments of Ophthalmology and 2Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland; 4Omnisyntheses, Madison, Wisconsin (no longer exists); and 6Cellgate, Inc., Redwood City, California.

PURPOSE. Polyamine analogues inhibit tumor growth in vitro and in vivo, and oligoamines with a chain length of 10, 12, or 14 are particularly potent. This study was conducted to investigate the effect of the decamines CGC-11144 and CGC-11150 in a mouse model of choroidal neovascularization (CNV).

METHODS. Mice with laser-induced rupture of Bruch’s membrane were given intraperitoneal, intravitreous, or periocular injection of CGC-11144, CGC-11150, or vehicle, and after 14 days, they were perfused with fluorescein-labeled dextran, and the area of CNV was measured on choroidal flatmounts by image analysis. In some groups of mice, treatments were started 7 days after rupture of Bruch’s membrane to determine the effect of the agent on established CNV. Electroretinograms (ERGs) were performed to assess the effects on retinal function, and histopathology was used to evaluate retinal structure.

RESULTS. Intraperitoneal injection of 10 or 20 mg/kg CGC-11144 or CGC-11150 resulted in small but significant reductions in the area of CNV. Intravitreous injection of 20 µg CGC-11144 or CGC-11150 on days 0 and 7 after rupture of Bruch’s membrane resulted in a ~40% reduction in the area of CNV, with a similar reduction after periocular injections of 0.2 mg CGC-11144 three times a week for 2 weeks. Both intravitreous and periocular delivery of CGC-11144 also caused significant regression of established CNV. Within 2 days of periocular injection of CGC-11144, there was apoptosis in CNV lesions, but not in normal blood vessels or other retinal cells. Periocular injections of D,L-{alpha}-difluoromethyl-ornithine (DFMO), which decreases polyamine levels by a different mechanism, also inhibited CNV. There was no decline in ERG amplitudes or abnormal retinal morphology after daily injections of 0.2 mg CGC-11144 for 2 weeks, but a single intravitreous injection compromised retinal structure and function.

CONCLUSIONS. Periocular delivery of the polyamine analogues may be a useful approach for the treatment of CNV.





This article has been cited by other articles:


Home page
IOVSHome page
Y. Fu, M. L. Ponce, M. Thill, P. Yuan, N. S. Wang, and K. G. Csaky
Angiogenesis Inhibition and Choroidal Neovascularization Suppression by Sustained Delivery of an Integrin Antagonist, EMD478761
Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 5184 - 5190.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Association for Research in Vision and Ophthalmology